Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)

Background/aim: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. Materials and methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients’ database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch. Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group. Conclusion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.

Anahtar Kelime: Fingolimod disease modifying treatment treatment switch glatiramer acetate beta interferon

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120. doi: 10.1177/1352458517751049.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(Pt 3):606-16. doi: 10.1093/ brain/awl007.
3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112 (6):1419-28. doi: 10.1093/ brain/112.6.1419.
4. Ziemssen T, Piani-Meier D, Bennett B, Johnson C, Tinsley K, Trigg A et al. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. J Med Internet Res 2020;22(2):e16932. doi: 10.2196/16932.
5. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long- term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry2014;85(1):67-75. doi: 10.1136/jnnp-2012-304333.
6. Koch M, Kingwell E, Rieckmann P, Tremlett H, Neurologists UMC. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2010;81(9):1039-43. doi: 10.1136/jnnp.2010.208173.
7. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2016;11:CD009333. doi: 10.1002/14651858.CD009333. pub3.
8. Efendi H, Yandım Kuşcu, D. Multipl Skleroz tanı ve tedavi kılavuzu. İstanbul: Galenos; 2018.
9. Saleem S, Anwar A, Fayyaz M, Anwer F, Anwar F. An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis. Cureus 2019;11(7):e5246. doi: 10.7759/cureus.5246.
10. Thomas K, Proschmann U, Ziemssen T. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother2017;18(15):1649-60. doi: 10.1080/14656566.2017.1373093.
11. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009;158(5):1173-82. doi: 10.1111/j.1476-5381.2009.00451.x.
12. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010;362(5):387- 401. doi: 10.1056/NEJMoa0909494.
13. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13(6):545-56. doi: 10.1016/S1474- 4422(14)70049-3.
14. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402- 15. doi: 10.1056/NEJMoa0907839.
15. Izquierdo G, Damas F, Paramo MD, Ruiz-Pena JL, Navarro G. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS One 2017;12(4):e0176174. doi: 10.1371/journal.pone.0176174.
16. Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S et al. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Curr Med Res Opin 2014;30(9):1849-55. doi: 10.1185/03007995.2014.921144.
17. Mazibrada G, Sharples C, Perfect I. Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK. Mult Scler J Exp Transl Clin 2018;4(4):2055217318801638. doi: 10.1177/2055217318801638.
18. Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm 2019;6(3):e548. doi: 10.1212/ NXI.0000000000000548.
19. Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait. CNS Drugs 2014;28(9):817-24. doi: 10.1007/s40263-014-0185-z.
20. Uzunköprü C, Beckmann Y, Türe S. Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting. Eur Neurol 2021;84(3):200-5. doi: 10.1159/000514828.
21. Braune S, Grimm S, van Hovell P, Freudensprung U, Pellegrini F, Hyde R et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol 2018;265(12):2980-92. doi: 10.1007/s00415-018-9083-5.
22. He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M et al. Comparison of switch to fingolimod or interferon beta/ glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147.
23. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin 2013;29(12):1647-56. doi: 10.1185/03007995.2013.847411.
24. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One 2014;9(2):e88472. doi: 10.1371/journal.pone.0088472.
25. Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M et al. Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurol Ther 2017;6(1):91-102. doi: 10.1007/s40120-017-0064-x.
26. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-73. doi: 10.1016/s1474-4422(17)30470-2.
27. Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M et al. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. BMC Neurol 2017;17(1):150. doi: 10.1186/ s12883-017-0913-3.
28. Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL et al. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020;78(1):1-13. doi: 10.1001/ jamaneurol.2020.2950.
29. D’Amico E, Patti F, Zanghì A, Lo Fermo S, Chisari CG, Zappia M. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Rev Clin Pharmacol 2018;11(5):531-6. doi: 10.1080/17512433.2018.1449643.
30. Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL et al. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020. doi: 10.1001/jamaneurol.2020.2950.
31. Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol 2017;264(12):2436-49. doi: 10.1007/s00415-017-8642-5.

APA	Tuncer a, Kürtüncü M, TERZI H, Uygunoglu U, Göncüoğlu C, YUCEYAR N, ekmekci o, Turkoglu R, Soysal A, Koseoglu M, Boz C, Beckmann Y, turan ö, DEMIRKIRAN D, Akman-Demir G, Altunrende B, Aydin Canturk I, shugaiv e, özcan a, Kamisli O, Acar Ozen N, Gozubatik-Celik R, Petek Balcı B, Efendi H, Egilmez Sarıkaya C, Akcali A, Kilinc Toprak M, canbaz kabay s, KIZILAY F, Sevim S, Baran Gazaloglu G, Demir C, BALGETİR F, nefati K, Sariahmetoglu H, olmez c, Mavi K, YÜKSEL S, ışık n, Saip S, Karabudak R, Siva A, ERAKSOY M (2023). Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). , 323 - 332. 10.55730/1300-0144.5588
Chicago	Tuncer aslı,Kürtüncü Murat,TERZI HACI MURAT,Uygunoglu Ugur,Göncüoğlu Cansu,YUCEYAR NUR,ekmekci ozgul,Turkoglu Recai,Soysal Aysun,Koseoglu Mesrure,Boz Cavit,Beckmann Yesim,turan ömer faruk,DEMIRKIRAN DURUHAN MELTEM,Akman-Demir Gulsen,Altunrende Burcu,Aydin Canturk Ilknur,shugaiv erkingül,özcan abdulcemal,Kamisli Ozden,Acar Ozen Nazire Pinar,Gozubatik-Celik Rabia Gokcen,Petek Balcı Belgin,Efendi Hüsnü,Egilmez Sarıkaya Cansu,Akcali Aylin,Kilinc Toprak Munire,canbaz kabay sibel,KIZILAY Ferah,Sevim Serhan,Baran Gazaloglu Gulcan,Demir Caner Feyzi,BALGETİR FERHAT,nefati Kiylioglu,Sariahmetoglu Hande,olmez cagcan,Mavi Kamil,YÜKSEL SÜHA,ışık nihal,Saip Sabahattin,Karabudak Rana,Siva Aksel,ERAKSOY MEFKURE Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). (2023): 323 - 332. 10.55730/1300-0144.5588
MLA	Tuncer aslı,Kürtüncü Murat,TERZI HACI MURAT,Uygunoglu Ugur,Göncüoğlu Cansu,YUCEYAR NUR,ekmekci ozgul,Turkoglu Recai,Soysal Aysun,Koseoglu Mesrure,Boz Cavit,Beckmann Yesim,turan ömer faruk,DEMIRKIRAN DURUHAN MELTEM,Akman-Demir Gulsen,Altunrende Burcu,Aydin Canturk Ilknur,shugaiv erkingül,özcan abdulcemal,Kamisli Ozden,Acar Ozen Nazire Pinar,Gozubatik-Celik Rabia Gokcen,Petek Balcı Belgin,Efendi Hüsnü,Egilmez Sarıkaya Cansu,Akcali Aylin,Kilinc Toprak Munire,canbaz kabay sibel,KIZILAY Ferah,Sevim Serhan,Baran Gazaloglu Gulcan,Demir Caner Feyzi,BALGETİR FERHAT,nefati Kiylioglu,Sariahmetoglu Hande,olmez cagcan,Mavi Kamil,YÜKSEL SÜHA,ışık nihal,Saip Sabahattin,Karabudak Rana,Siva Aksel,ERAKSOY MEFKURE Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). , 2023, ss.323 - 332. 10.55730/1300-0144.5588
AMA	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). . 2023; 323 - 332. 10.55730/1300-0144.5588
Vancouver	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). . 2023; 323 - 332. 10.55730/1300-0144.5588
IEEE	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M "Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)." , ss.323 - 332, 2023. 10.55730/1300-0144.5588
ISNAD	Tuncer, aslı vd. "Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)". (2023), 323-332. https://doi.org/10.55730/1300-0144.5588

APA	Tuncer a, Kürtüncü M, TERZI H, Uygunoglu U, Göncüoğlu C, YUCEYAR N, ekmekci o, Turkoglu R, Soysal A, Koseoglu M, Boz C, Beckmann Y, turan ö, DEMIRKIRAN D, Akman-Demir G, Altunrende B, Aydin Canturk I, shugaiv e, özcan a, Kamisli O, Acar Ozen N, Gozubatik-Celik R, Petek Balcı B, Efendi H, Egilmez Sarıkaya C, Akcali A, Kilinc Toprak M, canbaz kabay s, KIZILAY F, Sevim S, Baran Gazaloglu G, Demir C, BALGETİR F, nefati K, Sariahmetoglu H, olmez c, Mavi K, YÜKSEL S, ışık n, Saip S, Karabudak R, Siva A, ERAKSOY M (2023). Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences, 53(1), 323 - 332. 10.55730/1300-0144.5588
Chicago	Tuncer aslı,Kürtüncü Murat,TERZI HACI MURAT,Uygunoglu Ugur,Göncüoğlu Cansu,YUCEYAR NUR,ekmekci ozgul,Turkoglu Recai,Soysal Aysun,Koseoglu Mesrure,Boz Cavit,Beckmann Yesim,turan ömer faruk,DEMIRKIRAN DURUHAN MELTEM,Akman-Demir Gulsen,Altunrende Burcu,Aydin Canturk Ilknur,shugaiv erkingül,özcan abdulcemal,Kamisli Ozden,Acar Ozen Nazire Pinar,Gozubatik-Celik Rabia Gokcen,Petek Balcı Belgin,Efendi Hüsnü,Egilmez Sarıkaya Cansu,Akcali Aylin,Kilinc Toprak Munire,canbaz kabay sibel,KIZILAY Ferah,Sevim Serhan,Baran Gazaloglu Gulcan,Demir Caner Feyzi,BALGETİR FERHAT,nefati Kiylioglu,Sariahmetoglu Hande,olmez cagcan,Mavi Kamil,YÜKSEL SÜHA,ışık nihal,Saip Sabahattin,Karabudak Rana,Siva Aksel,ERAKSOY MEFKURE Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences 53, no.1 (2023): 323 - 332. 10.55730/1300-0144.5588
MLA	Tuncer aslı,Kürtüncü Murat,TERZI HACI MURAT,Uygunoglu Ugur,Göncüoğlu Cansu,YUCEYAR NUR,ekmekci ozgul,Turkoglu Recai,Soysal Aysun,Koseoglu Mesrure,Boz Cavit,Beckmann Yesim,turan ömer faruk,DEMIRKIRAN DURUHAN MELTEM,Akman-Demir Gulsen,Altunrende Burcu,Aydin Canturk Ilknur,shugaiv erkingül,özcan abdulcemal,Kamisli Ozden,Acar Ozen Nazire Pinar,Gozubatik-Celik Rabia Gokcen,Petek Balcı Belgin,Efendi Hüsnü,Egilmez Sarıkaya Cansu,Akcali Aylin,Kilinc Toprak Munire,canbaz kabay sibel,KIZILAY Ferah,Sevim Serhan,Baran Gazaloglu Gulcan,Demir Caner Feyzi,BALGETİR FERHAT,nefati Kiylioglu,Sariahmetoglu Hande,olmez cagcan,Mavi Kamil,YÜKSEL SÜHA,ışık nihal,Saip Sabahattin,Karabudak Rana,Siva Aksel,ERAKSOY MEFKURE Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences, vol.53, no.1, 2023, ss.323 - 332. 10.55730/1300-0144.5588
AMA	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences. 2023; 53(1): 323 - 332. 10.55730/1300-0144.5588
Vancouver	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE). Turkish Journal of Medical Sciences. 2023; 53(1): 323 - 332. 10.55730/1300-0144.5588
IEEE	Tuncer a,Kürtüncü M,TERZI H,Uygunoglu U,Göncüoğlu C,YUCEYAR N,ekmekci o,Turkoglu R,Soysal A,Koseoglu M,Boz C,Beckmann Y,turan ö,DEMIRKIRAN D,Akman-Demir G,Altunrende B,Aydin Canturk I,shugaiv e,özcan a,Kamisli O,Acar Ozen N,Gozubatik-Celik R,Petek Balcı B,Efendi H,Egilmez Sarıkaya C,Akcali A,Kilinc Toprak M,canbaz kabay s,KIZILAY F,Sevim S,Baran Gazaloglu G,Demir C,BALGETİR F,nefati K,Sariahmetoglu H,olmez c,Mavi K,YÜKSEL S,ışık n,Saip S,Karabudak R,Siva A,ERAKSOY M "Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)." Turkish Journal of Medical Sciences, 53, ss.323 - 332, 2023. 10.55730/1300-0144.5588
ISNAD	Tuncer, aslı vd. "Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)". Turkish Journal of Medical Sciences 53/1 (2023), 323-332. https://doi.org/10.55730/1300-0144.5588